We believe Eden Research's product portfolio of launched and pipeline opportunities provides a strong foundation for near- and mid-term revenue growth. Our forecasts see revenues growing to c£5.0m in FY24E from £1.8m in FY22A, supported by the core products and pipeline, with the seed treatment expected to contribute to revenues in FY24E. The company has announced it is conditionally raising £9m, gross, which it will use to support the launch of its new seed treatment, Ecovelex, in partnership w ....
